News Archive

Partners HealthCare is a global leader in healthcare research and development, with an immense capacity for innovation.

Partners HealthCare Innovation is the system’s business development arm that commercializes the insights and discoveries of researchers and clinicians at Boston-based Massachusetts General Hospital, Brigham and Women’s Hospital, Massachusetts Eye and Ear, and McLean Hospital, all of which are Harvard Medical School affiliates. The 125-member team was responsible for $154 million in commercial and investment income last year and at any given time is working on 2,000-plus active agreements.

Herndon, VA, Sept. 25, 2019 (GLOBE NEWSWIRE) — The Center for Innovative Technology (CIT) announced today the Commonwealth Research Commercialization Fund (CRCF) Request for Proposals (RFP) for FY2020.

The CRCF accelerates Virginia’s economic growth by supporting high-potential technology commercialization projects at Virginia’s public and private institutions of higher education, technology companies, and federal labs and nonprofit research organizations. A single solicitation for approximately $2.5 million will be offered in FY2020, through five programs: Commercialization, SBIR Matching Funds, STTR Matching Funds, Eminent Researcher Recruitment, and Matching Funds.

The product would reverse the effects of chemicals that disrupt nerve function for military and other emergency situations.

Image: Bob Kramer is president and CEO of Emergent BioSolutions. COURTESY EMERGENT BIOSOLUTIONS

A Baltimore medical device firm that aims to prevent kidney injury was awarded the $25,000 grand prize in the Beta City Venture Capital Pitch Competition.

Renalert was chosen as the winner of the live competition that took place Thursday evening during the fifth annual Beta City, a startup demo and networking event put on by Betamore and Sagamore Ventures at City Garage in South Baltimore. About 30 companies applied to the competition this year, and Renalert was one of five finalists chosen to present their concepts to a panel of judges. This year’s judges included representatives from Brown Advisory, Pitch Creator, Emerging Technology Centers, Johns Hopkins Tech Ventures and We Capital.

Image: Betamore Chairman Greg Cangialosi (middle) awarded Renalert CEO Aaron Chang (right) the grand prize for this year’s Beta City Venture Capital Pitch Competition. MORGAN EICHENSEHR

GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Services, valued at approximately $6.3 million over two years, for the continued development of AP007, the company’s sustained-release nalmefene formulation for the treatment of addiction in opioid use disorder (OUD). AP007 is an extended-release formulation of nalmefene, an opioid receptor antagonist, intended to continually release an effective dose of nalmefene for up to three months and to be administered through intramuscular injection. The award is being made under the Helping to End Addiction Long-term Initiative, or the NIH HEAL Initiative, which was launched to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management.

In September 2012, when National Institutes of Health (NIH) neurologist Chris Austin took charge of a new translational science center, he faced a host of skeptics. In launching the new center, NIH Director Francis Collins said he wanted to re-engineer drug development to speed new treatments to the clinic. But some accused NIH of wanting to become a drug company or solve the pharmaceutical industry’s challenges—a notion one former CEO likened to believing in fairies. It fell to Austin to prove that the National Center for Advancing Translational Sciences wasn’t going to compete with industry, but could give it new tools. After 7 years, the jury is still out.

ROCKVILLE, Md., Sept. 30, 2019 /PRNewswire/ — Emmes today announced that it was ranked as one of the 100 largest private companies in the Washington metropolitan area. The ranking is compiled annually by the Washington Business Journal.

The Emmes Corporation Logo (PRNewsFoto/The Emmes Corporation)

The company was ranked as the 83rd largest private company this year. Its most recently reported revenues were more than $114 million, and about 600 of the company’s 725 employees work in the Washington area.

WASHINGTON, Sept. 23, 2019 /PRNewswire/ — Children’s National Hospital and the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) announce the six winners of the $150,000 “Make Your Medical Device Pitch for Kids!” competition, each receiving a $25,000 award and the opportunity to participate in NCC-PDI’s recently launched “Pediatric Device Innovator Accelerator Program” led by MedTech Innovator. The six winners, who presented medical devices designed to improve Neonatal Intensive Care Unit (NICU) care, emerged from a field of 11 finalists. Each participant delivered their five-minute live pitch presentation to a panel of 25 esteemed judges during the 7th Annual Pediatric Device Innovation Symposium hosted by Children’s National.

Our Senior Consultant and Cluster Lead Boaz Van Driel just returned from his fruitful visit with our collaborators BioHealth Innovation, Inc.

This trip was a vital step in laying our foundations for our expansion in the United States and we look forward to our bright, united future!